1 April 2023 false No description of principal activity Taxfiler 2024.5 03567687business:PrivateLimitedCompanyLtd2023-04-012024-03-31 035676872023-03-31 035676872023-04-012024-03-31 03567687business:AuditExempt-NoAccountantsReport2023-04-012024-03-31 03567687business:FilletedAccounts2023-04-012024-03-31 035676872024-03-31 03567687business:Director12023-04-012024-03-31 03567687business:Director22023-04-012024-03-31 03567687business:Director32023-04-012024-03-31 03567687business:Director42023-04-012024-03-31 03567687business:Director52023-04-012024-03-31 03567687business:Director62023-04-012024-03-31 03567687business:CompanySecretary12023-04-012024-03-31 03567687business:RegisteredOffice2023-04-012024-03-31 035676872023-03-31 03567687core:WithinOneYear2024-03-31 03567687core:WithinOneYear2023-03-31 03567687core:ShareCapitalcore:PreviouslyStatedAmount2024-03-31 03567687core:ShareCapitalcore:PreviouslyStatedAmount2023-03-31 03567687core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-03-31 03567687core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-03-31 03567687core:PreviouslyStatedAmount2024-03-31 03567687core:PreviouslyStatedAmount2023-03-31 03567687business:SmallEntities2023-04-012024-03-31 03567687countries:EnglandWales2023-04-012024-03-31 03567687core:LandBuildings2023-04-012024-03-31 03567687core:PlantMachinery2023-04-012024-03-31 03567687core:MotorVehicles2023-04-012024-03-31 03567687core:IntangibleAssetsOtherThanGoodwill2023-03-31 03567687core:IntangibleAssetsOtherThanGoodwill2024-03-31 03567687core:LandBuildings2023-03-31 03567687core:PlantMachinery2023-03-31 03567687core:MotorVehicles2023-03-31 03567687core:LandBuildings2024-03-31 03567687core:PlantMachinery2024-03-31 03567687core:MotorVehicles2024-03-31 03567687business:OrdinaryShareClass12023-04-012024-03-31 03567687business:OrdinaryShareClass12022-04-012023-03-31 035676872022-04-012023-03-31 iso4217:GBP xbrli:shares xbrli:pure
Company Registration No. 03567687 (England and Wales)
Inpharmation Limited Unaudited accounts for the year ended 31 March 2024
Inpharmation Limited Unaudited accounts Contents
Page
- 2 -
Inpharmation Limited Company Information for the year ended 31 March 2024
Directors
Gary Johnson Karen Johnson Samuel Johnson Kim Robinson Nicholas Taylor Robert Watson
Secretary
Karen Johnson
Company Number
03567687 (England and Wales)
Registered Office
Evidence House Stokenchurch Business Park Ibstone Road Stokenchurch HP14 3FE United Kingdom
Accountants
Blue Cube Accountants Limited Britwell Grange Britwell Road Burnham SL1 8DF
- 3 -
Inpharmation Limited Statement of financial position as at 31 March 2024
2024 
2023 
Notes
£ 
£ 
Fixed assets
Intangible assets
12,188 
12,188 
Tangible assets
1,979,735 
2,041,595 
1,991,923 
2,053,783 
Current assets
Debtors
992,667 
712,188 
Cash at bank and in hand
4,252,824 
4,399,955 
5,245,491 
5,112,143 
Creditors: amounts falling due within one year
(701,132)
(936,123)
Net current assets
4,544,359 
4,176,020 
Total assets less current liabilities
6,536,282 
6,229,803 
Provisions for liabilities
Deferred tax
(16,222)
(20,286)
Net assets
6,520,060 
6,209,517 
Capital and reserves
Called up share capital
106 
105 
Profit and loss account
6,519,954 
6,209,412 
Shareholders' funds
6,520,060 
6,209,517 
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 14 October 2024 and were signed on its behalf by
Karen Johnson Director Company Registration No. 03567687
- 4 -
Inpharmation Limited Notes to the Accounts for the year ended 31 March 2024
1
Statutory information
Inpharmation Limited is a private company, limited by shares, registered in England and Wales, registration number 03567687. The registered office is Evidence House, Stokenchurch Business Park Ibstone Road, Stokenchurch, HP14 3FE, United Kingdom.
2
Accounting policies
Basis of preparation
These financial statements have been prepared in compliance with FRS 102, ’The Financial Reporting Standard applicable to the UK and Republic of Ireland’ including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.
Presentation currency
The accounts are presented in £ sterling.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
Intangible fixed assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. The patents and licences are not currently being amortised.
Tangible fixed assets and depreciation
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Land & buildings
2% Straight Line
Plant & machinery
20% Reducing Balance
Motor vehicles
20% Reducing Balance
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. Current or deferred taxation assets and liabilities are not discounted. Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
Deferred taxation
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
- 5 -
Inpharmation Limited Notes to the Accounts for the year ended 31 March 2024
Pension costs
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.
Research and development
Expenditure on research and development is written off in the year in which it is incurred.
Foreign exchange
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rates of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
3
Intangible fixed assets
Other 
£ 
Cost
At 1 April 2023
12,188 
At 31 March 2024
12,188 
Amortisation
At 1 April 2023
- 
At 31 March 2024
- 
Net book value
At 31 March 2024
12,188 
At 31 March 2023
12,188 
4
Tangible fixed assets
Land & buildings 
Plant & machinery 
Motor vehicles 
Total 
£ 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At cost 
At 1 April 2023
2,146,027 
281,389 
53,315 
2,480,731 
Additions
- 
308 
- 
308 
At 31 March 2024
2,146,027 
281,697 
53,315 
2,481,039 
Depreciation
At 1 April 2023
200,486 
219,170 
19,480 
439,136 
Charge for the year
42,921 
12,480 
6,767 
62,168 
At 31 March 2024
243,407 
231,650 
26,247 
501,304 
Net book value
At 31 March 2024
1,902,620 
50,047 
27,068 
1,979,735 
At 31 March 2023
1,945,541 
62,219 
33,835 
2,041,595 
- 6 -
Inpharmation Limited Notes to the Accounts for the year ended 31 March 2024
5
Debtors
2024 
2023 
£ 
£ 
Amounts falling due within one year
Trade debtors
968,188 
694,937 
Accrued income and prepayments
24,473 
17,246 
Other debtors
6 
5 
992,667 
712,188 
6
Creditors: amounts falling due within one year
2024 
2023 
£ 
£ 
VAT
21,582 
16,159 
Trade creditors
44,895 
21,374 
Taxes and social security
129,178 
436,053 
Other creditors
16,118 
29,933 
Loans from directors
8,477 
1,516 
Accruals
480,882 
431,088 
701,132 
936,123 
7
Share capital
2024 
2023 
£ 
£ 
Allotted, called up and fully paid:
106 Ordinary shares of £1 each
106 
105 
Shares issued during the period:
1 Ordinary shares of £1 each
1 
8
Average number of employees
During the year the average number of employees was 37 (2023: 37).
- 7 -